Genelux (GNLX) Revenue & Revenue Breakdown
Genelux Revenue Highlights
Latest Revenue (Y)
$8.00K
Genelux Revenue by Period
Genelux Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $8.00K | -95.29% |
| 2023-12-31 | $170.00K | -98.46% |
| 2022-12-31 | $11.07M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
Genelux generated $8.00K in revenue during NA 2024, up -95.29% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Genelux Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $896.00K | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $8.00K | -99.45% |
| 2023-12-31 | $1.46M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | -100.00% |
| 2023-03-31 | $170.00K | 150.00% |
| 2022-12-31 | $68.00K | -99.38% |
| 2022-09-30 | $11.00M | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
Genelux generated - in revenue during Q2 2025, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Genelux Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| SLN | Silence Therapeutics | $43.26M | $224.00K |
| ACIU | AC Immune | $14.80M | - |
| CLLS | Cellectis | $755.00K | $4.53M |
| GNLX | Genelux | $8.00K | - |
| CADL | Candel Therapeutics | - | - |
| ALDX | Aldeyra Therapeutics | - | - |
| CTNM | Contineum Therapeutics, Inc. Class A | - | - |
| LXEO | Lexeo Therapeutics | - | - |
| DRTS | Alpha Tau Medical | - | - |
| LYEL | Lyell Immunopharma | - | $15.00K |
| MREO | Mereo BioPharma Group | - | - |